Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04910685
Title	(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Blueprint Medicines Corporation
Indications	indolent systemic mastocytosis
Therapies	Elenestinib
Age Groups:	adult \| child \| senior
Covered Countries	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| BEL \| AUT \| AUS